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Abstract
Background: High quality evidence indicates that aspirin is effective in reducing colorectal polyps; and numerous
epidemiological studies point towards an ability to prevent colorectal cancer. However the role of Aspirin as an
adjuvant agent in patients with established cancers remains to be defined. Recently a nested case-control study
within the Nurses Health cohort suggested that the initiation of Aspirin after the diagnosis of colon cancer reduced
overall colorectal cancer specific mortality. Although this data is supportive of Aspirin’s biological activity in this
disease and possible role in adjuvant therapy, it needs to be confirmed in a randomized prospective trial.
Methods/Design: We hypothesize through this randomized, placebo-controlled adjuvant study, that Aspirin in
patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve survival in this patient
population over placebo control. The primary endpoint of this study is Disease Free Survival and the secondary
Endpoint is 5 yr Overall Survival. This study will randomize eligible patients with Dukes C or high risk Dukes B
colorectal cancer, after completion of surgery and standard adjuvant chemotherapy (+/- radiation therapy for rectal
cancer patients) to 200 mg Aspirin or Placebo for 3 years. Stratification factors include study centre, rectal or colon
cancer stage, and type of adjuvant chemotherapy (exposed/not exposed to oxaliplatin). After randomization,
patient will be followed up with 3 monthly assessments whilst on study drug and for a total of 5 years. Patients
with active peptic ulcer disease, bleeding diathesis or on treatment with aspirin or anti-platelet agents will be
excluded from the study.
Discussion: This study aims to evaluate Aspirin’s role as an adjuvant treatment in colorectal cancer. If indeed
found to be beneficial, because aspirin is cheap, accessible and easy to administer, it will positively impact the lives
of many individuals in Asia and globally.
Trials Registration: Clinicaltrials.gov: NCT00565708
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Background
Colorectal cancer is the third most common cancer
worldwide with almost 1 million new cases diagnosed
each year. It is now also the third leading cause of cancer
mortality in men and women with more than half of
diagnosed patients dying from the disease [1]. Over the
past 3 decades, the age-standardized incidence rate for
colorectal cancer has increased two to fourfold in Asian
countries such as China, Japan, South Korea and Singa-
pore [2]. Mortality rates in Asian countries have risen
concomitantly and in Singapore colon cancer has
recently surpassed lung cancer as the commonest cancer
with incidence rates now amongst the highest in Asia [3].
With the rising rates of cancer, a fundamental shift of
the cancer burden has also occurred between the devel-
oped and developing world. This problem, highlighted in
the 2008 WHO World Cancer Report, warned of a dispro-
portionate number of cancer deaths occurring in develop-
ing countries. Currently of the annual 12 million new
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cancer cases diagnosed and the 7.6 million cancer deaths
worldwide; 5.6 million new cases and 4.7 million cancer
deaths occurred in developing countries [4]. By the year
2020, it is predicted that changes in the demographics of
the population in developing nations will lead to approxi-
mately 70% of all new cancers occurring in lower income
countries [5]. Efforts therefore will have to be made to
develop novel therapies that are not only effective but also
accessible to the people who need them [6].
Adjuvant chemotherapy
Adjuvant 5-FU based chemotherapy has been proven to
improve relative overall survival in duke’s C colon can-
cer by approximately 25-35%, in a series of landmark
clinical trials [7-11] conducted over the past 3 decades -
and has become standard therapy following surgery for
colorectal cancer.
In 2004, the MOSAIC study was able to establish a
new standard of care. For the first time, a new agent
(oxaliplatin), was shown to improve 3 year disease free
survival (DFS) over infusional 5FU alone [12]. After 7
years of follow up, oxaliplatin was associated with an
absolute 2.5% survival gain for Dukes C colon cancer.
Although Oxaliplatin-5FU combinations have become
the new standard of care for Dukes C colon cancer;
neurotoxicity and thrombocytopenia continue to remain
significant challenges in the clinic.
Since the MOSAIC study was published in 2004, no
other new agents have been shown to improve colon
cancer outcomes. For example, although highly effective
in the metastatic setting, Irinotecan chemotherapy has
failed in three large randomised adjuvant studies - the
EORTC PETACC-3, ACCORD and CALGB 89803
[13-15]. The failure of irinotecan is particularly discon-
certing, since there are so few agents with a similar
track record of efficacy in the metastatic setting. How-
ever, the consistent negative results in these high profile
studies, means that further trials with Irinotecan are
unlikely to be undertaken in the future [16]. With con-
ventional chemotherapy combinations appearing to be
reach their therapeutic index, strategic focus shifted to
biological therapies including monoclonal antibodies to
Vascular Endothelial Growth Factor (VEGF) and Epider-
mal Growth Factor Receptor (EGFR).
Biological Therapies
The idea of using anti-VEGF monoclonal antibodies
such as Bevacizumab, upfront in the adjuvant setting is
one that carries particular scientific merit. The concept
of the “angiogenic switch” means that tumours more
than 1 mm would need to eventually grow their own
blood supply in order to survive [17]. Consequently,
bevacizumab should theoretically be even more effective,
when used to treat tumours that are small, and
particularly vulnerable to vascular disruption. Two large
adjuvant bevacizumab studies have been undertaken to
prove this concept - the NSABP C08 trial and the
AVANT study. However, the results of the NSABP-C08
study published in 2011 was negative for its primary
endpoint. More than 2000 patients were randomised to
either 5FU/Oxaliplatin or the same chemotherapy with
Bevacizumab and after a median follow up of 3 years,
there was no significant difference in disease free survi-
val between the 2 populations [18].
Cextuximab, a chimeric human-mouse monoclonal
antibody to VEGF receptor is currently under develop-
ment as an adjuvant agent for colon and rectal cancers.
Although Cetuximab is highly effective in the metastatic
setting, the preliminary results of the NCCTG Inter-
group 0147 study evaluating its use in the adjuvant set-
ting for kras mutated and wild-type tumors - indicates
that it neither improves disease free survival nor overall
survival [19].
Cox 2 specific inhibitors
Since the discovery that cox-2 enzyme was consistently
over-expressed in colon cancer; a large body of pre-clin-
ical scientific evidence has emerged implicating cox and
PGE2 in cancer initiation and propagation [20,21]. This
has culminated in two large randomised trials evaluating
Cox-2 specific inhibitors as specific adjuvant agents in
colon cancer - VICTOR and the EORTC PETAAC 5.
Both these trials were discontinued prematurely follow-
ing concerns about the cardiovascular safety for these
agents when in extended use. PETAAC 5 was a double
blind randomised placebo controlled study, and evalu-
ated celecoxib or placebo for 3 years and used DFS as a
primary endpoint [22].
Launched in 2001, VICTOR randomised patients with
stage II or III colon and rectal cancer that had com-
pleted standard adjuvant therapy to 2 years of rofecoxib,
5 years of rofecoxib or placebo, before it was prema-
turely suspended in 2005 when rofecoxib was withdrawn
from the market [23]. In contrast to the EORTC study,
VICTOR only randomized patients after completion of
standard adjuvant therapy and it also included rectal
cancers and stage II disease. In the analysis of 2300
patients who had been treated with study drug for a
median of 7 months, there was no difference observed
between the two treatment groups in terms of disease
free survival and overall survival [24]. However due to
the short median exposure to study medication and the
failure to achieve accrual target, it is not possible to
make any conclusion concerning efficacy.
Aspirin
The first suggestion that NSAIDs/Aspirin may be bene-
ficial in the adjuvant setting derives from a pre-planned
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review of patients in the CALGB 89803 study. This
study randomised stage III colon cancer patients to 5FU
chemotherapy with or without irinotecan, and in addi-
tion to the primary study, incorporated a pre-planned
analysis to compare outcomes of patients who were on
Aspirin or cox2 inhibitors. Of the 830 patients surveyed,
75 patients and 41 patients used Aspirin and Cox-2
inhibitors regularly. Amongst Aspirin and Cox2 users,
the hazard ratio for disease recurrence was 0.45 (95% CI
0.21-0.97) and recurrence and/or death 0.48 (95%CI
0.24-0.99). No difference however was noted with para-
cetamol use [25].
More recently, a nested case control study within the
Nurses Health Study) cohort suggested that the initia-
tion of Aspirin after the diagnosis of colon cancer was
able to reduce colorectal cancer specific mortality (HR
0.53, CI 0.33-0.86) on multivariate analysis [26]. Regular
aspirin use after diagnosis was associated with an
impressive lowering of colorectal cancer-specific mortal-
ity among participants in whom primary tumors overex-
pressed COX-2 (multivariate HR, 0.39; 95% CI, 0.20-
0.76). This is in contrast to patients with tumours that
had weak or absent cox2 expression where aspirin use
was not associated with lower risk (multivariate HR,
1.22; 95% CI, 0.36-4.18). This suggests a biologically
plausible mechanism for aspirin’s activity.
Although the results from both these studies are
extremely exciting and have the potential to open up
new avenues in our understanding of cancer biology;
they are observational studies and so may be due to bias
and confounding. Therefore these findings need to be
evaluaed in a prospective randomized placebo-controlled
study which is the the aim of the ASCOLT study.
Methods/Design
Objectives
The primary endpoints for this study are Disease Free
Survival for all eligible patients (colon, rectal, dukes C
colon, high risk Dukes B colon, and Rectal cancer com-
bined) and Disease Free Survival for colon cancer sub-
jects (Dukes C and high risk Dukes B colon cancer).
The secondary endpoint for this study is 5 year Overall
Survival.
Study population and design
This is a double blind, placebo-controlled, randomized
study investigating aspirin in Duke B and C colorectal
cancer. Patients who have complete resection of their
primary tumour and who have completed standard adju-
vant therapy (chemotherapy ± radiotherapy) within 90
days, and without bleeding diathesis or contraindication
to aspirin will be eligible for the study. Patients on
aspirin, anti-platelet therapy, anti-coagulation, ischemic
heart disease, stroke, peripheral vascular disease or
uncontrolled hypertension will be excluded from this
study. Adjuvant chemotherapy is not specified but
should consist of at least 3 months of a 5FU based che-
motherapy. Rectal cancers may additionally have radio-
therapy administered in either adjuvant or neoadjuvant
fashion. Eligible subjects will be randomised to the
study in a 1:1 ratio to either Aspirin 200 mg or match-
ing placebo once daily for 3 years. Patients will be ran-
domised in a competitive recruitment process from
participating centres over 5 years. Randomisation will be
done via direct web randomisation, and patients will be
stratified by study centre, tumour type (Dukes C colon,
high risk Dukes B colon cancer & rectal cancer sub-
groups) and type of adjuvant chemotherapy received
(exposed/not exposed to oxaliplatin). The steps for
direct web randomization are as follows:
1. Authorized study centre personnel will randomise
the patient via a password-protected internet web
site http://randomise.cteru.com.sg.
2. The following information will be entered and the
patient will be stratified by:
- Study centre
- Tumour type (Dukes C colon, high risk Dukes
B colon cancer & rectal cancer sub-groups)
- Type of adjuvant chemotherapy received
(exposed/not exposed to oxaliplatin)
3. The randomisation system will then determine the
treatment arm and provide the subject number to be
used for the patient.
4. The site monitor/CRA will be informed immedi-
ately in the event that the web randomisation is not
successful.
After randomisation, patients will have 3 monthly
assessments for 3 years (month 3 to month 36) followed
by 6 monthly assessments for additional 2 years (Figure
1).
Endpoint assessment
Disease recurrence is defined as any one of the following
- unequivocal radiological evidence of colorectal cancer
recurrence, recurrence detected by digital rectal exami-
nation (DRE), positive histology or cytology (i.e. perito-
neal or pleural cytology), colonoscopic evidence of local
cancer recurrence at the previous operation site, detec-
tion of a new colon or rectal primary tumour. Disease
free survival is defined as the time from randomisation
to the time of disease recurrence or death from any
cause and overall survival is defined as the time from
randomisation to the time of death from any cause.
Compliance is defined as taking the study drug for more
than 70% of days during each scheduled follow-up visit
throughout the treatment duration of 3 years.
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Sample size calculation
The total trial size will be 2660 patients, 1330 rando-
mised to Aspirin group and 1330 randomised to Placebo
group. In the sub-groups, there should be at least 2000
high risk Dukes B or Dukes C colon cancer patients,
others are rectal cancer patients
It is assumed that 3-years disease free survival rate for
Dukes B colon cancer, Dukes C colon cancer and rectal
cancer are 65% after standard adjuvant chemotherapy;
and the attrition rate is 5%. Therefore, the total trial size
(2660) will be sufficient to detect a 6% absolute differ-
ence of disease free survival rate for all subjects between
the two treatments, with a two-sided logrank test of 5%
type I error and 90% power; further, our 3-year DFS
rate for colon cancer is assumed to be 65%, which is
similar to the entire group as a whole, the size of colon
cancer (2000) will be sufficient to detect a 6% absolute
difference of disease free survival rate for colon cancer
 
Dukes C / high risk Dukes B colon  cancer or 
Rectal cancer subgroups
Complete Surgical Resection of Tumor





200 mg OD for 3 years 
Placebo
200 mg OD for 3 years
3 monthly follow-up for 3 years
followed by
6 monthly follow-up for 2 years
3 monthly follow-up for 3 years
followed by
6 monthly follow-up for 2 years
Figure 1 CONSORT Diagram. OD, once daily.
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between the two treatments, with a two-sided logrank
test of 5% type I error and 80% power.
Statistical Analysis
All statistical analyses will be carried out on an inten-
tion-to-treat basis. In the analysis of disease free survi-
val, a patient is considered to have an event if he/she
relapses after randomisation. The starting point for dis-
ease free survival is the date of randomisation and the
terminating point is the date of first relapse or date of
death, whichever occurs first. Patients in whom there
has been no evidence of disease after treatment are cen-
sored at the date of last follow-up. Similarly, the overall
survival time is computed from the date of randomisa-
tion to the date when the patient is last known to be
alive.
Survival curves will be constructed using the Kaplan-
Meier method and life table estimates of 3 and 5 year
survival rates will be calculated. The efficacy of Aspirin
will be estimated by the HR and its corresponding 95%
CI and the Cox proportional hazards model will be used
to adjust the HRs for the trial stratification factors (site,
type of tumour and type of adjuvant chemotherapy).
Stratified analysis and other non-proportional hazard
models (which allow for the effects of covariates to vary
over time) would be considered when the proportional
hazards assumption is not valid. This assumption will be
checked by using graphical methods and statistical tests
during the modelling. Results from non-proportional
models such as stratified Cox model or Cox model with
time-dependent covariates will then be reported as the
main analysis (depending on the appropriateness of each
model to the actual data).
The secondary endpoint will be analysed in a similar
manner to the primary endpoints. Tests for interaction
for the colon cancer subgroups and other subgroups
will be conducted. Analyses of primary and secondary
endpoints will be repeated within the subgroups defined
by ethnicity and tumour type. Analysis of primary and
secondary endpoints will also be repeated for compliant
and non-compliant subjects. In addition, cumulative
incidence function will be estimated and the two treat-
ment arms will be compared using Gray’s method if
competing risks are present.
Interim analysis
An independent data and safety monitoring committee
(DSMC) will be established to review the interim results
of the study. Two interim analyses are scheduled. The
first interim analysis should be done after 540 patients
have been recruited (estimated to take between two to
three years) or mid-point of the targeted recruitment
period, and the second interim analysis should be done
once 540 patients have been followed up for 3 years
(approximately between five to six years). The aim of
the first interim analysis is toxicity whereas the aim of
the second interim analysis is disease free survival and
overall survival as well as toxicity profile. The results of
the second interim analysis will not be the sole criteria
for deciding whether to terminate accrual or report the
results early. Rather they will provide a guideline to aid
in the decision, which will also take into account the
characteristics of the patients, nature of toxicities, rele-
vant external results. Most importantly, the sample size
will be re-estimated. Apart from the reason of safety,
which may caution otherwise, the minimum trial size
will remain as 2660 as initially planned.
Anticipated side effects of Aspirin
Side effects that occasionally occur are gastrointestinal
disorders such as nausea, vomiting, diarrhoea, and slight
gastrointestinal blood loss which in exceptional cases
can lead to anaemia. Gastrointestinal ulcers may rarely
develop, in some circumstances with haemorrhaging
and perforation. Dizziness and ringing in the ear can
occur as symptoms of overdosage, especially in children
and elderly patients.
Rare cases of hypersensitivity reactions (e.g. difficulty
in breathing, skin reaction) can occur as have isolated
cases of liver and kidney function disturbances, and
severe skin reactions have been reported. The absolute
annual increase risk attributable to Aspirin for major
bleeding, major gastrointestinal bleeding and intracranial
haemorrhage has been estimated in a large meta-analysis
to stand at 0.13%, 0.12% and 0.03% respectively [27].
Blinding
The patient, the study team including the investigator(s)
and the sponsor will be blinded. However, the study sta-
tistician who prepares the randomisation list and the
designated unblinded personnel who prepare the study
drug packaging and labelling will not be blinded. The
study statistician will prepare the sealed emergency
code-break envelopes and distribute to the study centres
accordingly. The envelopes will contain the treatment
assignment, with the corresponding subject number
printed on it, and will be kept at site by the investigator
or designated person. At interim analysis, only the study
statistician will be unblinded.
Treatment modification
The study drug should be started immediately but no
later than 2 weeks after randomisation. The patient will
be treated with the same study drug for 3 years. Treat-
ment may be modified according to guidelines provided
in the study protocol and according to clinical judge-
ment and best medical practices. Patients who need to
undergo elective surgery or other interventional
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procedures may stop the study drug 5 days prior to sur-
gery and recommence the study drug upon recovery
(when haemostasis is secured or when the patient is
able to take orally). Patients who develop anaphylaxis,
angioedema or gastrointestinal bleeding should stop the
study drug immediately and should not undergo re-chal-
lenge to study drug. Patients who are unable to tolerate
200 mg of study drug may have the dose reduced to 100
mg.. The reason and date of dose reduction will be
clearly documented. Proton pump inhibitors (PPIs) will
be used in patients who have symptoms of epigastric
discomfort. They should be given at adequate doses and
continued for at least 3 months. PPIs are preferable to
H2 antagonists. Antacids (i.e. magnesium trisilicate,
magnesium carbonate) should not be given in place of
PPIs; however, they may be used to supplement these
agents. Patients who undergo gastroscopy should be
screened for helicobacter pylori and treated accordingly.
Treatment discontinuation
Study drug will be stopped immediately if there is a dis-
ease recurrence confirmed by CT, histology or cytology.
In the event of an SAE related to study drug, the study
drug will be stopped immediately but patients will con-
tinue to be followed up until 5 years after
randomisation.
Assessment and follow-up
Patients will begin screening after the last dose of stan-
dard therapy (chemotherapy ± radiotherapy). This will
consist of written informed consent, medical history
(asthma, diabetes, ischaemic heart disease, stroke, gas-
trointestinal ulcers or bleeding, alcohol history, smok-
ing), family history of colorectal cancer, current
medication, vital signs (body weight, height, BP), and
blood investigations within 4 weeks of randomization
(haematology, urea, creatinine, liver function tests,
CEA). Full colonoscopy, CT abdomen ± pelvis, Chest
X’Ray (or CT thorax) and ECG will be valid if per-
formed within 12 months prior to screening.
Patients will be followed up at 3-monthly intervals
whilst on study drug (i.e. month 3, 6, 9, 12, 15, 18, 21,
24, 27, 30, 33, and 36). Concomitant medication, records
of adverse events (AE) and severe adverse events (SAE),
CEA, haemoglobin, and surveillance colonoscopy
(month 6 and 30) and surveillance CT scans (month 6,
18 and 30) will be recorded during visits. Following
completion of study drug, patients will be assessed at 6-
monthly intervals (month 42, 48, 54 and 60).
Discussion
This study represents the first randomized aspirin trial,
and a novel therapeutic approach, in the treatment of
established colorectal cancer. The failure of 3 large
randomized trials to show benefit for irinotecan in the
adjuvant treatment of colorectal cancer and the recent
disappointing failure of anti-VEGF and anti-EGFR
monoclonal antibodies to improve survival makes the
search for effective new agents all the more urgent.
Although substantial clinical, epidemiological [28-33]
and pre-clinical data [34-44] points to a possible biologi-
cal role for NSAIDs, and in particular Aspirin, in influ-
encing the progression of colorectal cancer - to date no
clinical trial of Aspirin in the adjuvant setting has been
undertaken. Two large randomized studies exploring
cox-2 inhibitors, the EORTC PETACC and the VICTOR
trial had been undertaken, but were suspended prema-
turely, due to concerns of cardiovascular toxicity. More
recently a new study by the CALGB exploring celecoxib
in Stage 3 colon cancer has been initiated in US. Never-
theless, concerns still remain regarding cardiovascular
toxicity in prolonged use. Aspirin by contrast is a non-
selective cox inhibitor and is cardio-protective - and one
of the most widely used drugs with a long history of
use. If aspirin is indeed found to be beneficial, because
it is cheap and easy to administer, it may have a larger
impact for many patients in Asia and globally.
The optimal dose of Aspirin as an adjuvant agent for
colorectal cancer is not known. There have been, to date,
no randomised Aspirin trials exploring secondary preven-
tion as an endpoint. Non-randomised studies evaluating
Aspirin as a primary prevention agent have suggested that
a dose of 325 mg a day for 5 years is effective [32]. In the
analysis of the Nurses Health Study, regular use of stan-
dard Aspirin (325 mg) twice or more per week was shown
to reduce the incidence of colorectal cancers. In contrast,
analysis from randomised cardiovascular and stroke trials
did not support additional benefit above 75 mg [45]. In
the polyp prevention study by Baron et al, a lower dose
(81 mg) of Aspirin appeared to be at least equally as effec-
tive as an intermediate dose (325 mg) in preventing recur-
rence of polyps [46]. In addition, dose escalation studies in
normal human subjects using mucosal PGE2 as a biomar-
ker have suggested that 81 mg Aspirin dose was sufficient
to significantly suppress rectal mucosal PGE2 levels and
did so to an equivalent extent as higher doses [47,48]. Our
study using a 200 mg daily dose, falling into the middle of
the range of doses in earlier studies - reflects the ongoing
uncertainty concerning optimal dose. Whilst recognizing
that standard dose Aspirin (i.e. 325 mg OD) may be the
most logical dose to pursue in this clinical trial, we feel
that a 200 mg intermediate dose would be more tolerable
in our predominantly Asian trial population.
To our best knowledge, this trial represents the first
attempt to evaluate aspirin as an adjuvant agent in
Dukes B and C colorectal cancer. If shown to be benefi-
cial, the results of this trial will have a major impact on
the management of a globally important disease.
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Trial Status
The trial was started in March 2009. To date more than
130 patients have been randomised. The study has been
expanded to 35 sites.
ASCOLT Investigators
The trial and publication is on behalf of the ASCOLT
Investigators: The Sixth Affiliate Hospital: JP Wang,
YH Deng, X Jian; Foshan Hospital: W Wang;Yonsei
Cancer Centre: JK Roh, AJ Bae, SJ Shin; Penang
Adventist Hospital: TA Raj, E Nathan; Hospital Kuala
Lumpur: R Khong, F Lau, A Deniel; Pantai Hospital
KL: J Low; Pantai Hospital AK: D Tan; University
Malaya Medical Centre: GF Ho, BMY Mastura, AC
Roslani; University Kebangsaan Malaysia Medical
Centre: M Azrif; Queen Mary Hospital: T Yau, WL
Law; Dr Sardjito Hospital: J Kurnianda, I Purwanto, K
Widayati; Dharmais National Cancer Centre Hospital:
A Soemardi, S Syafei; L Mellinas, R Andalusia, S Noor-
wati; Cipto Mangunkusumo General Hospital: I Basir,
M Abdullah, F Maengkom, I Rinaldi, G B Prajogi; Johns
Hopkins Singapore IMC: G Lopes, G Ku, L Bharwani,
A Chopra, A Chang; National Cancer Centre Singa-
pore: CK Tham, S Ong, SP Choo, SK Lo, WH Koo, HY
Lim, I Tan, KH Lim. Tan Tock Seng Hospital: R Sim;
Kidwai Memorial Institute of Oncology: L Dasappa;
Nizam’s Institute of Medical Sciences: G Sadashivudu;
Tata Memorial Hospital: Mohandas Mallath; All India
Institute of Medicine: A Sharma; Christian Medical
College: RT Chacko; GKNM Valavadi Narayanasamy
Cancer Centre: B Sivanesan, A Rajkumar; Amrita Insti-
tute of Medical Sciences: TS Ganesan; Regional Can-
cer Centre: A Sajeed; King Fahad Medical City: A
Ismail, Taipei Medical University Hospital: CI Hsieh,
PL Wei, LJ Juo; TMU Shuang Ho Hospital: TY Chao,
CM Chen, YY Hsieh, TC Chang; Wan Fang Hospital:
GM Lai, YW Su, CM Chou; Taipei Vetrans General
Hospital: CC Yen, JK Lin, JH Liu, TC Lin, HW Teng;
Chang Hua Hospital: HC Chen, CS Chang, SY Huang,
CC Wang, SY Lin, CY Chung, JT Lin, SZ Hsu; Koo
Foundation Sun Yat Sen Cancer Centre: IP Huang,
CH Chen, CC Chen, KC Huang; National Cheng Kung
University Hospital: JC Lee, PC Lin, WC Su, BW Lin,
SC Lin; Siriraj Hospital: T Kullathorn, C Akewanlop, P
Dankulchai, Y Chansilpa, T Akaraviputh; King Chula-
longkorn Hospital: S Chucheep, PA Jirawat, P Atit-
tharnsakul, K Tantiplachiva; Phillipines General
Hospital: DL Sacdalan, D Parreno;
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